Norway's Hofseth Biocare Q1 revenue falls on production disruption

Overview

• Norway consumer and pet health firm's Q1 revenue fell yr/yr due to plant maintenance

• Gross margin rose as portfolio shifted toward bioactive, clinically differentiated ingredients

• Company completed private placement after Q1, restoring equity and liquidity position

Outlook

• Company expects Q2 2026 revenue to be comparable to Q2 last year despite lower production

• HBC expects to return to full production by end of Q3 2026

• Several new OmeGo product launches planned for Q3 with leading global brands

Result Drivers

• PRODUCTION DISRUPTION - Scheduled maintenance and overhaul at the Midsund plant reduced production volumes and delayed shipments, impacting Q1 revenue

• B2C PROFITABILITY IMPROVEMENT - Consumer & Pet Health segment gross margin improved, supported by Amazon channel clean-up and better supply reliability

Company press release:

Key Details

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .